Doxorubicin encapsulated nanocells - EnGeneIC

Drug Profile

Doxorubicin encapsulated nanocells - EnGeneIC

Alternative Names: EGFREDVDox; Doxorubicin packaged EDV™ nanocells - EnGeneIC; Doxorubicin-loaded EDV nanocells; EGFR(V)-EDV-Dox; EnGeneIC Delivery Vehicle™; EnGeneIC Dream Vector™; VEDVDox

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EnGeneIC
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action Immunostimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma
  • Phase I Solid tumours
  • Preclinical Brain cancer

Most Recent Events

  • 09 Aug 2017 Phase-I clinical trials in Solid tumours (Treatment-naive) in Australia (IV) (EnGeneIC pipeline, August 2017)
  • 02 Mar 2017 Doxorubicin encapsulated nanocells receives Orphan Drug status for Glioblastoma in USA
  • 25 Oct 2016 Phase-I clinical trials in Glioblastoma (Recurrent, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02766699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top